SCHEMBL6681822

SCHEMBL6681822

Cn1c2c(c(=O)n(Cc3ccc(C#N)cc3)c1=O)SC(C(=O)OCc1ccc(F)cc1)=CN2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
MAPK14 Q16539 1/20 0.35
MAPT P10636 2/20 0.35
CNR2 P34972 2/20 0.35
CNR1 P21554 1/20 0.35
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PKM P14618 1/20 0.35
PARG Q86W56 2/20 0.34
HSD17B10 Q99714 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6678562 0.90 L3MBTL1 (0.42) LMNAALDH1A1TDP1TSHRSMN1; SMN2
SCHEMBL6790883 0.86 TP53 (0.36) KDM4ELMNAALDH1A1MAPTTSHR
SCHEMBL6679546 0.85 TRPA1 (0.43) KDM4ELMNAHTTALDH1A1CNR2
SCHEMBL7123266 0.81 KDM4E (0.39) KDM4ELMNAHTTALDH1A1GAA
SCHEMBL6680969 0.80 KDM4E (0.38) KDM4ELMNAHTTALDH1A1GAA
SCHEMBL6684265 0.75 MMP1 (0.43) KDM4ELMNAALDH1A1RXFP1MAPT
SCHEMBL6791261 0.74 TRPA1 (0.54) KDM4ELMNAHTTALDH1A1MAPT
SCHEMBL6678512 0.71 SMN1; SMN2 (0.45) LMNAALDH1A1GAATSHRSMN1; SMN2
SCHEMBL6679503 0.71 TRPA1 (0.42) LMNAALDH1A1RXFP1MAPTSMN1; SMN2
SCHEMBL7122539 0.71 KDM4E (0.40) KDM4ELMNAHTTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 KDM4E 819/4885LMNA 3842/4885HTT 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.